Friday, December 16, 2016

New features in LexiComp


Wolters Kluwer
Clinical Drug Information
 
 
 
Lexicomp Online Updates
 
■ 
ENHANCED: Updated Formulary Monograph Service Interface
■ 
NEW: Pharmacogenomics Summary Monographs
■ 
NEW: Hazardous Drug Handling Monograph Field
■ 
CHANGE: Removal of Web Search Feature
 
ENHANCED: Updated Formulary Monograph Service Interface
 
Subscribers to the Formulary Monograph Service (FMS) will now be able to access information on recently released and investigational drugs in a new, convenient interface that looks and feels like Lexicomp Online. The more user-friendly navigation is designed to provide a better overall experience within your Lexicomp workflow.
 
To access the FMS module, click the Formulary Monograph Service button on the blue toolbar atop every page of Lexicomp Online. It opens a drop-down menu with four options:
 
■ 
Pharmacy & Therapeutics Reviews (P and T Reviews) – full monographs
■ 
Summary Reviews – summary monographs
■ 
Drug Use Evaluations (DUEs) – forms to evaluate a given drug's use
■ 
New Drug Reviews Index – monthly digests summarizing the new monographs and DUEs that have been added
 
Each drop-down option will display an index for users to search for the review or DUE they are seeking.
 
 
 
NEW: Summary Pharmacogenomics Monographs
 
Lexicomp users will now be able to efficiently connect to point-of-care pharmacogenomics information for specific drugs with new summary pharmacogenomics monographs.
 
Through Lexicomp, Clinical Drug Information has long been at the forefront of providing pharmacogenomics content and helping professionals incorporate this emerging and growing field into their practice. Summary pharmacogenomics monographs facilitate quicker access to actionable content, focusing on a single drug or drug class. Monographs include the following:
 
■ 
Quality of evidence rating and management considerations emphasized at the top of every monograph
■ 
Management section providing more information on the drug or class
■ 
Focused summary discussion of scientific and clinical studies data relevant to the drug or class
■ 
Links to the related monograph from our in-depth pharmacogenomics database, which will continue to discuss details about the relevant gene, including incidence, variability across population, pathophysiologic information, and more
 
Summary pharmacogenomics monographs can also be accessed through direct Infobutton links in an EMR or from integrated drug-gene contraindications clinical screening alerts. Speak to your Clinical Drug Information representative for more information on programming these links.

 
ENHANCED: New Monograph Fields
 
Lexicomp has added and updated fields to monographs in its Lexi-Drugs core drug information database:
 
■ 
FDA Approval Date – Provides the date of a drug’s FDA approval.
■ 
Last Updated – Provides the date that Clinical Drug Information last updated the monograph.
■ 
Hazardous Drugs Handling Considerations – Information on hazardous drug handling has now been consolidated in a single field. Based on National Institute for Occupational Safety and Health (NIOSH) criteria, the field includes information to assist with receiving, handling, administering, or disposing of hazardous drugs. It is included in monographs for 300 drugs on the NIOSH list of hazardous agents that require special handling considerations, as well as in monographs for new and similar drugs that meet NIOSH criteria. (Field includes statements to confirm if monograph is for a NIOSH-listed drug or one that met extrapolated criteria.)
 
 
CHANGE: Removal of Web Search Feature
 
Please note that the Web Search feature has been removed from the More Clinical Tools drop-down menu on the blue toolbar in Lexicomp Online. For additional sources outside Lexicomp, please use the Other Clinical Links option on the More Clinical Tools menu for quick access to professional healthcare industry websites.
 
 
Wolters Kluwer Health
 
 
 
 
Support | Contact Us | Privacy Policy |
© 2016 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.
 

No comments:

Post a Comment